FRONTIER SCIENCE | PUBLICATIONS

The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

OVERVIEW

Although some countries have implemented widespread colonoscopy screening, most European countries have not introduced it because of uncertainty regarding participation rates, procedure-related pain and discomfort, endoscopist performance, and effectiveness.

Title of publication

Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

AUTHORS

Bretthauer, M., Kaminski, M.F., Løberg, M., Zauber, A.G., Regula, J., Kuipers, E.J., Hernán, M.A., McFadden, E., Sunde, A., Kalager, M. and Dekker, E., Lansdorp-Vogelaar, I., Garborg, K., Rupinski, M., Spaander, M., Bugajski, M., Høie, O., Stefansson, T., Hoff, G., Adami, H-O., for the Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group

PUBLICATION REFERENCE

JAMA Internal Medicine | Volume 176 | Issue 7 | 894-902 | 2016

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more
APHINITY | European Journal of Cancer (EJC)

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

read more
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

Feb 15, 2022

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

read more